HC Wainwright restated their buy rating on shares of Cybin (NYSE:CYBN - Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $190.00 price objective on the stock.
Separately, Canaccord Genuity Group dropped their price target on shares of Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a research report on Thursday, November 14th.
View Our Latest Stock Report on Cybin
Cybin Stock Down 4.4 %
CYBN stock traded down $0.44 during midday trading on Monday, reaching $9.59. The company had a trading volume of 179,038 shares, compared to its average volume of 199,038. Cybin has a 1 year low of $6.50 and a 1 year high of $19.85. The company has a market cap of $191.70 million, a P/E ratio of -1.44 and a beta of 0.44. The company's 50-day moving average is $9.83.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cybin stock. Sanctuary Advisors LLC acquired a new position in Cybin Inc. (NYSE:CYBN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 131,252 shares of the company's stock, valued at approximately $36,000. Institutional investors and hedge funds own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Featured Stories
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
